



## **Evolution Research Group Risk Mitigation Response Plan COVID-19**

**Site: Clinical Pharmacology of Miami (CPMI), Miami,  
Florida**

**Version Date: 17APR2020**

---

### **Purpose:**

This response plan's purpose is to provide structure surrounding the management and contingency plans during the COVID-19 pandemic or other crisis as determined by Corporate Management at Evolution Research Group (ERG).

This response plan is applicable to all staff at the Site location noted in the header of this document. It is the responsibility of the Site Director at the location to ensure proper execution of this plan.

This plan will be reviewed and further amended on a routine basis as information is learned or provided as applicable from the World Health Organization (WHO), the Center for Disease Control (CDC), the Food and Drug Administration (FDA) and other regulatory bodies as applicable to ensure consistency with expectations, rules and guidelines. As the plan content is amended it will be pushed to the ERG portfolio sites to be promptly populated with their site-specific information.

### **Plan:**

#### **A. General Volunteer/Subject Management**

- a. Volunteers should be contacted by phone prior to arriving at the facility to ensure they are asymptomatic. When calling our subjects/ caregivers to remind them of their appointments, ask whether they are suffering from respiratory symptoms such as a cough, fever, or shortness of breath. If so, they should be rescheduled once they are feeling better. These questions should be included in a prescreening/screening evaluation and the potential subject rescheduled once they are symptom free and approved to come in by a PI/Sub-I or Medical Director. The volunteer should then be instructed to contact their Primary Care Provider (PCP) and the sponsor should be notified, where applicable of the out of window visit due to this reason.
  - i. Note: Only Caregivers will be permitted to attend visits with subjects. Subjects will be reminded that any guests that accompany them will be requested to remain outside of the clinic.



## **Evolution Research Group Risk Mitigation Response Plan COVID-19**

**Site: Clinical Pharmacology of Miami (CPMI), Miami,  
Florida**

**Version Date: 17APR2020**

---

- b. If a volunteer requires transportation to the clinic, the driver will make every effort to only pick up one volunteer at a time and disinfect in between rides. If additional subjects require pick up, the subjects must be alerted prior to arrival to ensure they are comfortable. Masks and gloves will be made available to those that require it prior to getting into the vehicle. The driver will take temperatures prior to entering the vehicle and documenting this.
  - i. Note: If a driving service is utilized, volunteer will be instructed to not get into the vehicle and come to the site if they don't feel well.
- c. Once volunteers arrive at the clinic, they will be required to have a temperature check prior to entering the facility and complete a health questionnaire (unless they were checked upon pick up from site transport). (see steps listed in section A, ii). They then must be instructed to wash their hands.
- d. Volunteers will only be taken to areas where they are required to be seen and don the necessary gloves or face masks as available or as instructed.
- e. Rooms that volunteers/study participants may be seen in must have all unnecessary items removed prior to entry and only the required equipment available (i.e. not the whole lab cart, iPads should be removed from their cases so they can be cleaned, designated BP cuffs should be used and the source chart should be kept outside of the designated room). Immediately after a volunteer is removed from a certain area, the room must be disinfected.
- f. Any deviations to any required study procedures must be documented, *in detail*, and rationale outlined as it relates to the pandemic.

### **B. Inpatient Visit Management**

- a. The subject census will be reduced to a size that can be appropriately managed to protect the safety of the staff and other subjects.
- b. Subjects presenting for study admission will be given appointments separated by a minimum of 15 mins.



## Evolution Research Group Risk Mitigation

### Response Plan COVID-19

Site: Clinical Pharmacology of Miami (CPMI), Miami,  
Florida

Version Date: 17APR2020

---

- c. Upon arrival to the facility all subjects will complete a health screen which consists of the completion of a health screening form and having their temperature checked (and pulse oximetry if determined by PI/SubI/Medical Director). If they pass the health screening, they will be instructed to wash their hands and don the mask provided by staff. **[Please note: Subjects will receive a new mask each day or as determined by the investigator].**
- d. Subjects will be escorted into individual procedure rooms by a staff member where admission activities will be performed.
- e. Upon completion of the admission activities subjects will be escorted into the phase 1 unit and placed in individual rooms or areas separated by the required distance as suggested by CDC guidelines.
- f. Subjects will be separated during their confinement to the facility.
- g. The number of staff members assigned to each subject will be limited.
- h. The subject areas will be disinfected after discharge.
- i. Should a subject begin to experience symptoms, they will be taken to a prepared quarantine room and isolated. The Investigator will be immediately alerted to exam the subject. Should the Investigator determine that the subject should seek additional medical care, the subject will be instructed to go to the closest Emergency room or urgent care facility. The sponsor will be notified immediately.

#### C. Outpatient Visit Management

- a. Subjects presenting for outpatient visits will be given appointments separated by a minimum of 15 mins.
- b. Upon arrival to the facility all subjects will complete a health screen which consists of the completion of a health screening form and having their temperature (and pulse oximetry if determined by PI/SubI/Medical Director). If they pass the health screening, they will be instructed to wash their hands and don the mask provided by staff.



## **Evolution Research Group Risk Mitigation**

### **Response Plan COVID-19**

**Site: Clinical Pharmacology of Miami (CPMI), Miami, Florida**

**Version Date: 17APR2020**

---

- c. Subjects will be escorted into individual procedure rooms by a staff member where admission activities will be performed.
- d. Staff members assigned to each subject will be limited.
- e. Procedure areas will be disinfected after each visit completion.
- f. Based on pandemic conditions, other precautions may be put in place to mitigate exposure risk. The site, in coordination with and approval from Sponsors, would eliminate the need for subjects to come to the site by performing remote visits with the use of video conferencing (ie: telemedicine).
  - i. Subjects would be supplied with necessary equipment (eg. vital signs machine, scales for measuring weight) and trained to perform protocol specific activities at home.
  - ii. For specific trials, subjects would be provided with enough Investigation Product so that self-administering can be performed at home under the supervision of a study staff member using video conferencing.

#### **D. Notification of Potential Participant or Visitor Exposure**

- a. As soon as a site has been notified of a participant or visitors' potential exposure in the community, the Site Director, PI/Medical Director, and the Chief Medical Officer must be notified immediately. The Incident must be documented according to the sites process.
- b. An evaluation will be conducted as to who should be communicated this information and next steps on prevention. The sponsor/CRO must be notified in a timely manner as to this information and to discuss next steps as it applies to participant safety and possible continuation/discontinuation in their trial, as applicable. Documentation should be maintained for all decisions and all notified parties. If the participant is active in a trial, then their symptoms must be documented as Adverse Events and further diagnosed upon a potential positive test/outcome. All instances must be reported to the IRB.



## Evolution Research Group Risk Mitigation Response Plan COVID-19

Site: Clinical Pharmacology of Miami (CPMI), Miami,  
Florida

Version Date: 17APR2020

---

### E. Remote Study Visits with Subjects

- a. Upon the determination and input from the sponsor and investigator site, remote study visits may be an acceptable deviation to on-site visits, pending a participant agrees to do the visit in this manner. All correspondence must be documented and filed in the Regulatory Binders as it applies to these decisions and subject source documents where applicable.
- b. The sponsor and investigator site must review what the remote visits would entail in conjunction with the FDA Guidance provided for the pandemic in question. It is ideal but not always mandatory to obtain IRB approval prior to executing any procedures that would be in the best interest of a subject's safety and well-being (e.g. continuing them in the study, terminating them from the study, the benefits of remaining on study drug, etc.).
- c. Investigational Product Dispensing may vary based on study, risk, or benefit to the subject. Special considerations must be made on a study by study basis as to whether IP may be mailed, picked up or dropped off. Further, if it is in the best interest of the participants safety and wellbeing to either continue them on study IP or not continue them on study IP, then this will be determined, and course of action documented. Temperature controls must also be considered. Once established this will be required to be outlined in the study plan developed by the sponsor and site, with IRB oversight at applicable intervals.
- d. If safety decisions must be made prior to IRB approval or notification, then IRB notification must be done at the first available opportunity.
- e. All decisions made must be documented *in detail* in the participants study files.
- f. Subjects will be contacted on an ongoing basis by site personnel to review study compliance and monitor for adverse events.



## **Evolution Research Group Risk Mitigation**

### **Response Plan COVID-19**

**Site: Clinical Pharmacology of Miami (CPMI), Miami,  
Florida**

**Version Date: 17APR2020**

---

#### **F. General Employee Management**

##### **a. General Precautions to be Taken by Staff**

- i. All staff are responsible to contact their supervisor immediately if they have any symptoms of illness or exposure that may increase risk of infection. The supervisor will work with the appropriate team to be determined if they should remain home, for how long, and assigned responsibilities and tasks if working from home is an option (dependent on illness). If a Site level Supervisor/Designee cannot be reached, they are to contact the Chief Medical Officer (CMO).
- ii. All staff are required to have their temperatures checked each time they present to the clinic for work. If a staff member is first to the clinic, they are responsible for recording their own temperature. Temperatures will be taken in the lobby or other designated entrance with an appropriate temperature recorder. Temperatures to be taken with a Non touch infrared thermometers. Should one not be available, other alternatives are acceptable with physician or NP approval. The staff member taking the temperature should wear protective gloves. If an individual's temperature is greater than or equal to 100.4 F, they will not be allowed into the facility pending further evaluation by the investigator.
- iii. While employees are onsite, in addition to wearing their required Personal Protective Equipment (PPE) while working with biohazard materials, all staff should wear personal protective equipment inclusive of gloves, disposable gowns/lab jacket, and face masks during any interaction with study participants and strongly encouraged if near other employees (less than 6 feet apart). Should supplies be low, contact the CMO on further directive.

##### **b. Modified Work Schedule**

- i. Schedules may be modified to limit exposure and infection risks and to adhere to governmental restrictions.



## Evolution Research Group Risk Mitigation

### Response Plan COVID-19

Site: Clinical Pharmacology of Miami (CPMI), Miami,  
Florida

Version Date: 17APR2020

---

- ii. Staff shifts will be modified such that there are 2 teams (Team A and Team B) working alternating shifts. Alternating shifts will consist of one team working on-site while the other team works remotely in one-week intervals. Teams will be divided so that there will be equal departmental representation on each team.

- c. Remote Work Opportunities

- i. If employees are required to work from home, Information Technology (IT) department will be contacted to confirm they have accessibility to all systems and hardware needed.
- ii. Employees must discuss and work with their Site Directors on what work may be able to be taken home, and what type of Chain of Custody of those items must be employed. ***NOTE: Under no circumstances can original source data or any Protected Health Information (PHI) of our volunteers be removed from the facilities.***
- iii. Should original source data or PHI of participants be needed to complete a remote task, then a protected electronic file (21 CFR Part 11 compliant) may be developed with restricted access so that the information may be uploaded for the purposes of data entry, data QC, etc. *A Note to File will be generated and filed in instances where remote data entry may be completed.*
- iv. Any emails sent to external email addresses that contain PHI or confidential information must be encrypted. All documents containing PHI or confidential information should be shared using SharePoint or OneDrive. (See section vii)
- v. Redaction of scanned documentation must be implemented to ensure appropriate protection of volunteers PHI. If documents must be printed at home to facilitate the work, then all copies must be saved and brought back into the clinic for destruction when able.



## **Evolution Research Group Risk Mitigation Response Plan COVID-19**

**Site: Clinical Pharmacology of Miami (CPMI), Miami,  
Florida**

**Version Date: 17APR2020**

---

- vi. Any data reviews or entries made must be verified against original source data upon returning to the clinic unless someone that is at the clinic can do the Source Data Verification on the employee's behalf.
- vii. SharePoint online provides a solution to CFR 21, Part 11 Requirements. Security and data integration are provided by the following features:

**Azure Active Directory Integration** – Only authorized accounts can access the system.

**Prevention of unauthorized users.** - SharePoint can prevent unauthorized users from accessing areas of the system, where electronic records are created and maintained. It is also possible to configure the record center with separate access controls.

**Restrict access to system administration.**

For additional safety, SharePoint can also restrict access to system administration and configuration by setting up security groups or permissions.

**Protect Data Records**

SharePoint can protect data records from deletion and enable their accurate retrieval. The SharePoint Information Management Policy feature is implemented, and retention policies are applied to various content types for a required period. Versioning is also setup to preserve copies of data records.

### **G. Notification of Potential Employee Exposure**

- a. As soon as an employee learns of any potential for exposure to a person with a positive result as it relates to the pandemic, (e.g. grocery store, place of worship, etc.), their Site Director and the Chief Medical Officer must be notified immediately.





## **Evolution Research Group Risk Mitigation**

### **Response Plan COVID-19**

**Site: Clinical Pharmacology of Miami (CPMI), Miami,  
Florida**

**Version Date: 17APR2020**

---

- b. An evaluation will be conducted as to who should be communicated this information and next steps on prevention. Documentation should be maintained for all decisions and all notified parties.
- c. The employee must remain at home for a minimum of 14 days post exposure and be asymptomatic prior to returning to work.

#### **H. Communication Management with Sponsors and CROs**

- a. All discussions and decisions made as they relate to the pandemic in question must be documented *in detail* and filed with the applicable studies. The participants that were active in those decisions must be identified, and signatures obtained when critical study impact decisions are made (e.g. Principal Investigator).
- b. Considerations must be made by the site if any remote activities will be entertained by the sponsor/CRO to ensure continued monitoring, close out visits, Study Initiation Visits, etc. Accommodations and resourcing must be factored in to ensure realistic timelines may be achieved. See Letter I below on Management of Remote Sponsor/CRO Visits.
- c. If ERG must decide to limit or even temporarily postpone activities at the clinical research site, a formal communication will be developed by Corporate Leadership to disseminate to the applicable clients.
- d. The IRBs must be notified in all scenarios to changes in trial execution. If it is not feasible to obtain IRB approval prior to executing some of the new contingency plans or decisions, then approval must be obtained by the CMO to proceed.

#### **I. Remote Sponsor/CRO Visits**

- a. Should remote monitoring, close out visits, audits, or meetings be requested, the Site Director will accommodate the requests unless other circumstances may prevent this (e.g. hold on beginning new trials would yield postponement of an SIV). If Remote Monitoring Visits/Close Outs or Audits will be considered and



## **Evolution Research Group Risk Mitigation Response Plan COVID-19**

**Site: Clinical Pharmacology of Miami (CPMI), Miami,  
Florida**

**Version Date: 17APR2020**

---

accommodated, then refer to *ERG Policy on Remote Study Monitoring During COVID-19* for guidance.

### **References**

[www.Cdc.gov](http://www.Cdc.gov)

[www.fda.gov](http://www.fda.gov)

[www.who.int](http://www.who.int)

[www.advarra.com](http://www.advarra.com)

### **Version History**

New